Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan

Cheng Kuo Cheng, Shih Jen Chen, Jiann Torng Chen, Lee Jen Chen, San Ni Chen, Wen Lu Chen, Sheng Min Hsu, Chien Hsiung Lai, Shwu Jiuan Sheu, Pei Chang Wu, Wei Chi Wu, Wen Chuan Wu, Chung May Yang, Ling Yeung, Ta Ching Chen, Chang Hao Yang

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)

Abstract

The management of neovascular age-related macular degeneration (nAMD) has taken a major stride forward with the advent of anti-VEGF agents. The treat-and-extend (T&E) approach is a refined management strategy, tailoring to the individual patient’s disease course and treatment outcome. To provide guidance to implementing anti-VEGF T&E regimens for nAMD in resource-limited health care systems, an advisory board was held to discuss and generate expert consensus, based on local and international guidelines, current evidence, as well as local experience and reimbursement policies. In the experts’ opinion, treatment of nAMD should aim to maximize and maintain visual acuity benefits while minimizing treatment burden. Based on current evidence, treatment could be initiated with 3 consecutive monthly injections. After the initial period, treatment interval may be extended by 2 or 4 weeks each time for the qualified patients (i.e. no BCVA loss ≥5 ETDRS letters and dry retina), and a maximum interval of 16 weeks is permitted. For patients meeting the shortening criteria (i.e. any increased fluid with BCVA loss ≥5 ETDRS letters, or presence of new macular hemorrhage or new neovascularization), the treatment interval should be reduced by 2 or 4 weeks each time, with a minimal interval of 4 weeks. Discontinuation of anti-VEGF may be considered for those who have received 2–3 consecutive injections spaced 16 weeks apart and present with stable disease. For these individuals, regular monitoring (e.g. 3–4 months) is recommended and monthly injections should be reinstated upon signs of disease recurrence.

Original languageEnglish
Article number25
JournalBMC Ophthalmology
Volume22
Issue number1
DOIs
Publication statusPublished - 2022 Dec

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan'. Together they form a unique fingerprint.

Cite this